Yuangui Chen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Yuangui Chen has a total of 53 co-authors. Here are the top co-authors by number of shared publications:
Haihua Lei
Department of Radiation Oncology, Fujian Medical University Union Hospital, Fuzhou, China
2 shared publicationsJiangshan Li
Department of Radiation Oncology, Fujian Medical University Union Hospital, Fuzhou, China
2 shared publicationsJiaxiang Gao
Department of Radiation Oncology, Fujian Medical University Union Hospital, Fuzhou, China
2 shared publicationsQianhong Chen
Fuzhou No. 8 School Sino-US Program, Fuzhou, China
2 shared publicationsTe Xu
Department of Radiation Oncology, Fujian Medical University Union Hospital, Fuzhou, China
2 shared publications- Xiaodong Wu
Radiation Oncology, Miami Neuroscience Center, Larkin Community Hospital, Miami, USA
2 shared publications
Latest Publications
- Open Access
- 10 July 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
Deep learning for patient-specific quality assurance of volumetric modulated arc therapy: predicting gamma passing rate based on accelerator dynamic log files
To predict and classify the gamma passing rate (GPR) for patient-specific quality assurance (PSQA) in VMAT using a deep learning approach based on accelerator dynamic log files. Dynamic log files of 438 VMAT plans were analyzed. GPR were measured by using Delta4. Using dynamic log files as inputs and GPR under five different criteria as outputs, the Resnet-based model was trained by a five-fold cross-validation method. The average absolute error (MAE), mean square error (MSE), root mean square error (RMSE), Spearman’s rank correlation coefficient (Sr), coefficient of determination (R 2 ), and Classification performance were calculated. In the test dataset, the predictive model demonstrated good agreement with measured GPR values across different gamma criteria, with MAE ranging from 0.59 to 2.05%, RMSE ranging from 1.02 to 3.94%, and R 2 ranging from 0.76 to 0.88. Significant correlations were observed between predicted and measured GPR values under all gamma criteria (Sr = 0.83–0.94, p < 0.001).For the classification models, the accuracy ranged from 0.87 to 0.96, while the AUC values ranged from 0.89 to 0.97 across different gamma criteria, indicating favorable classification performance. We developed a deep learning model that demonstrated promising performance in predicting and classifying GPR for VMAT PSQA. The model is promising as it streamlines the PSQA process and may reduces the associated workload, demonstrating substantial clinical potential.
- 10 July 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
Open AccessDeep learning for patient-specific quality assurance of volumetric modulated arc therapy: predicting gamma passing rate based on accelerator dynamic log files
To predict and classify the gamma passing rate (GPR) for patient-specific quality assurance (PSQA) in VMAT using a deep learning approach based on accelerator dynamic log files. Dynamic log files of 438 VMAT plans were analyzed. GPR were measured by using Delta4. Using dynamic log files as inputs and GPR under five different criteria as outputs, the Resnet-based model was trained by a five-fold cross-validation method. The average absolute error (MAE), mean square error (MSE), root mean square error (RMSE), Spearman’s rank correlation coefficient (Sr), coefficient of determination (R 2 ), and Classification performance were calculated. In the test dataset, the predictive model demonstrated good agreement with measured GPR values across different gamma criteria, with MAE ranging from 0.59 to 2.05%, RMSE ranging from 1.02 to 3.94%, and R 2 ranging from 0.76 to 0.88. Significant correlations were observed between predicted and measured GPR values under all gamma criteria (Sr = 0.83–0.94, p < 0.001).For the classification models, the accuracy ranged from 0.87 to 0.96, while the AUC values ranged from 0.89 to 0.97 across different gamma criteria, indicating favorable classification performance. We developed a deep learning model that demonstrated promising performance in predicting and classifying GPR for VMAT PSQA. The model is promising as it streamlines the PSQA process and may reduces the associated workload, demonstrating substantial clinical potential.
- Open Access
- 14 October 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 1-13
Dosimetric and radiobiological benefits of patient-specific respiratory motion management for liver tumor stereotactic body radiotherapy
Respiratory motion management was crucial importance in radiotherapy. Our study aimed to explore the dosimetric and radiobiological benefits of various respiratory motion management strategies in liver tumor patients undergoing stereotactic body radiotherapy (SBRT). Respiratory motion images of 23 liver tumor patients were obtained by 4DCT scan under abdominal compression (AC) and free-breathing (FB). Group A included all 23 patients, while group B focused on 11 patients with tumors < 5 cm in diameter. Dosimetric and radiobiological parameters were recorded and compared across three treatment plans for each patient: PlanFB, PlanAC, and PlanGAT(Respiratory gating). For dosimetric parameters, compared to PlanAC, PlanGAT further significantly reduced liver Dmean, Vd, V10Gy; right kidney Dmean; duodenum Dmean, D0.5cc, 1cc, 5cc, 10cc; intestine Dmean, D0.5cc, 5cc, 10cc; stomach Dmean and spinal cord Dmean, V5Gy in group A; however, in Group B, PlanGAT only showed significantly reductions in liver Dmean and duodenum Dmean, D5cc, 10cc. In terms of radiobiology, compared with PlanFB, PlanAC significantly reduced liver NTCP (p = 0.033) in Group B, whereas no difference was observed in Group A (p = 0.231). Additionally, compared to PlanAC, PlanGAT further reduced liver NTCP (p = 0.001), liver EUD (p < 0.001) and right kidney EUD (p < 0.001) in Group A; however, in Group B, PlanGAT did not significantly decrease liver NTCP (p = 0.136), indicating that AC offers comparable benefits to GAT. The Pearson’s correlations between the reductions in dosimetric and radiobiological parameters and tumor motion or target volume were stronger in Group B than in Group A under AC. So, GAT provides the greatest dosimetric and radiobiological benefits for liver tumors treated with SBRT, while AC offers comparable benefits for liver tumors with < 5 cm in diameter. Thus, given its technical simplicity, AC is recommended for liver tumors < 5 cm in diameter undergoing SBRT.
- 14 October 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 1-13
Open AccessDosimetric and radiobiological benefits of patient-specific respiratory motion management for liver tumor stereotactic body radiotherapy
Respiratory motion management was crucial importance in radiotherapy. Our study aimed to explore the dosimetric and radiobiological benefits of various respiratory motion management strategies in liver tumor patients undergoing stereotactic body radiotherapy (SBRT). Respiratory motion images of 23 liver tumor patients were obtained by 4DCT scan under abdominal compression (AC) and free-breathing (FB). Group A included all 23 patients, while group B focused on 11 patients with tumors < 5 cm in diameter. Dosimetric and radiobiological parameters were recorded and compared across three treatment plans for each patient: PlanFB, PlanAC, and PlanGAT(Respiratory gating). For dosimetric parameters, compared to PlanAC, PlanGAT further significantly reduced liver Dmean, Vd, V10Gy; right kidney Dmean; duodenum Dmean, D0.5cc, 1cc, 5cc, 10cc; intestine Dmean, D0.5cc, 5cc, 10cc; stomach Dmean and spinal cord Dmean, V5Gy in group A; however, in Group B, PlanGAT only showed significantly reductions in liver Dmean and duodenum Dmean, D5cc, 10cc. In terms of radiobiology, compared with PlanFB, PlanAC significantly reduced liver NTCP (p = 0.033) in Group B, whereas no difference was observed in Group A (p = 0.231). Additionally, compared to PlanAC, PlanGAT further reduced liver NTCP (p = 0.001), liver EUD (p < 0.001) and right kidney EUD (p < 0.001) in Group A; however, in Group B, PlanGAT did not significantly decrease liver NTCP (p = 0.136), indicating that AC offers comparable benefits to GAT. The Pearson’s correlations between the reductions in dosimetric and radiobiological parameters and tumor motion or target volume were stronger in Group B than in Group A under AC. So, GAT provides the greatest dosimetric and radiobiological benefits for liver tumors treated with SBRT, while AC offers comparable benefits for liver tumors with < 5 cm in diameter. Thus, given its technical simplicity, AC is recommended for liver tumors < 5 cm in diameter undergoing SBRT.
- Open Access
- 5 December 2023
- Published by Springer Nature in BMC Cancer
- Vol. 23 (1) , 1-11
Prognostic value of Hematoxylin and eosin staining tumor-infiltrating lymphocytes (H&E-TILs) in patients with esophageal squamous cell carcinoma treated with chemoradiotherapy
Background: Tumor-infiltrating lymphocytes (TILs) by routine hematoxylin and eosin staining (H&E-TILs) are a robust prognostic biomarker in various cancers. However, the role of H&E-TILs in esophageal squamous cell carcinoma (ESCC) treated with concurrent chemoradiotherapy (CCRT) has not been reported. The purpose of this study was to assess the prognostic value of H&E-TILs in ESCC treated with CCRT. Methods: The clinical data of 160 patients with ESCC treated with CCRT in our center between Jan. 2014 and Dec. 2021 were collected and retrospectively reviewed, and propensity score matching (PSM) analyses were performed. The H&E-TILs sections before CCRT were reassessed by two experienced pathologists independently. The H&E-TILs sections were classified into a positive group (+, > 10%) and a negative group (-, ≤ 10%) using 10% as the cutoff. The effects of H&E-TILs on overall survival (OS), progression-free survival (PFS), distant metastasis-free survival (DMFS), and locoregional recurrence-free survival (LRFS) were explored using the Kaplan‒Meier method, and the log-rank test was used to test the differences. Multivariable analysis was performed using the Cox proportion hazards model. Results: The short-term response to CCRT and the OS (P < 0.001), DMFS (P = 0.001), and LRFS (P < 0.001) rates were significantly different between the H&E-TILs (+) and H&E-TILs (-) groups. Subgroup analysis showed that H&E-TILs(+) with CR + PR group had a longer survival than H&E-TILs(-) with CR + PR, H&E-TILs(+) with SD + PD and H&E-TILs(-) with SD + PD group, respectively(P < 0.001). Furthermore, based on TCGA data, patients in the high TILs group had a better prognosis than those in the low TILs group. Multivariate analyses indicated that H&E-TILs and the short-term response to CCRT were the only two independent factors affecting OS, PFS, DMFS, and LRFS simultaneously, and H&E-TILs expression was associated with an even better prognosis for those patients with CR + PR. Conclusions: H&E-TILs may be an effective and beneficial prognostic biomarker for ESCC patients treated with CCRT. Patients with H&E-TILs (+) with PR + CR would achieve excellent survival. Further prospective studies are required to validate the conclusions.
- 5 December 2023
- Published by Springer Nature in BMC Cancer
- Vol. 23 (1) , 1-11
Open AccessPrognostic value of Hematoxylin and eosin staining tumor-infiltrating lymphocytes (H&E-TILs) in patients with esophageal squamous cell carcinoma treated with chemoradiotherapy
Background: Tumor-infiltrating lymphocytes (TILs) by routine hematoxylin and eosin staining (H&E-TILs) are a robust prognostic biomarker in various cancers. However, the role of H&E-TILs in esophageal squamous cell carcinoma (ESCC) treated with concurrent chemoradiotherapy (CCRT) has not been reported. The purpose of this study was to assess the prognostic value of H&E-TILs in ESCC treated with CCRT. Methods: The clinical data of 160 patients with ESCC treated with CCRT in our center between Jan. 2014 and Dec. 2021 were collected and retrospectively reviewed, and propensity score matching (PSM) analyses were performed. The H&E-TILs sections before CCRT were reassessed by two experienced pathologists independently. The H&E-TILs sections were classified into a positive group (+, > 10%) and a negative group (-, ≤ 10%) using 10% as the cutoff. The effects of H&E-TILs on overall survival (OS), progression-free survival (PFS), distant metastasis-free survival (DMFS), and locoregional recurrence-free survival (LRFS) were explored using the Kaplan‒Meier method, and the log-rank test was used to test the differences. Multivariable analysis was performed using the Cox proportion hazards model. Results: The short-term response to CCRT and the OS (P < 0.001), DMFS (P = 0.001), and LRFS (P < 0.001) rates were significantly different between the H&E-TILs (+) and H&E-TILs (-) groups. Subgroup analysis showed that H&E-TILs(+) with CR + PR group had a longer survival than H&E-TILs(-) with CR + PR, H&E-TILs(+) with SD + PD and H&E-TILs(-) with SD + PD group, respectively(P < 0.001). Furthermore, based on TCGA data, patients in the high TILs group had a better prognosis than those in the low TILs group. Multivariate analyses indicated that H&E-TILs and the short-term response to CCRT were the only two independent factors affecting OS, PFS, DMFS, and LRFS simultaneously, and H&E-TILs expression was associated with an even better prognosis for those patients with CR + PR. Conclusions: H&E-TILs may be an effective and beneficial prognostic biomarker for ESCC patients treated with CCRT. Patients with H&E-TILs (+) with PR + CR would achieve excellent survival. Further prospective studies are required to validate the conclusions.
- Open Access
Stereotactic Body Radiotherapy Boost with the CyberKnife for Locally Advanced Cervical Cancer: Dosimetric Analysis and Potential Clinical Benefits
(1) Aim: To compare the treatment plans of stereotactic body radiotherapy (SBRT) with CyberKnife (CK) and high-dose-rate (HDR) intracavitary/interstitial brachytherapy (IC/ISBT) and examine the feasibility of CK-SBRT as a viable alternative to BT in patients with locally advanced cervical cancer (LACC). (2) Methods: A BT plan of 28 Gy in four fractions delivered previously to 20 patients with LACC was compared with a CK plan based on the same CT images with structures delineation for BT. The SBRT treatment plan was further divided according to two different approaches, with the high-risk planning target volume (HR-PTV) defined by the high-risk clinical target volume (HR-CTV) without and with a 5 mm margin, which were named CK-CTV plan and CK-PTV plan, respectively. The dose distributions and dosimetric parameters of the target volumes and organs at risk (OARs) were recorded and compared for the three boost plans. Radiobiological metrics were calculated based on the EUD for the hybrid plans. Additionally, the relationship between tumor volume and tolerance doses for the OARs in the BT plan and CK-PTV plan was investigated. (3) Results: Target coverage was better with the CK plan than with the BT plan, as the D95%, D98%, HI and CI of the CK-CTV plan and CK-PTV plan were higher than those of the BT plan; an exception was the D50%. Similarly, the TCP of the target was also significantly in favor of the CK hybrid plans (p < 0.01). For the OARs, the CK-CTV plan was superior to the BT plan as regards the rectum D2cc, bladder D2cc and bladder Dmax. The CK-PTV plan could achieve dosimetric parameters comparable to those of the BT plan for OARs concerning the small residual tumor volume. The NTCP of the rectum for the WPI+CK-CTV plans was significantly lower than that of the WPI+BT plans (p < 0.01). (4) Conclusions: CK-based SBRT can achieve better target coverage, dose sparing for the OARs and radiobiological effects compared with the BT plan for tumors that are not excessively large. CK-based SBRT could be an alternative option to administer a radiation boost for patients with LACC.
Open AccessStereotactic Body Radiotherapy Boost with the CyberKnife for Locally Advanced Cervical Cancer: Dosimetric Analysis and Potential Clinical Benefits
(1) Aim: To compare the treatment plans of stereotactic body radiotherapy (SBRT) with CyberKnife (CK) and high-dose-rate (HDR) intracavitary/interstitial brachytherapy (IC/ISBT) and examine the feasibility of CK-SBRT as a viable alternative to BT in patients with locally advanced cervical cancer (LACC). (2) Methods: A BT plan of 28 Gy in four fractions delivered previously to 20 patients with LACC was compared with a CK plan based on the same CT images with structures delineation for BT. The SBRT treatment plan was further divided according to two different approaches, with the high-risk planning target volume (HR-PTV) defined by the high-risk clinical target volume (HR-CTV) without and with a 5 mm margin, which were named CK-CTV plan and CK-PTV plan, respectively. The dose distributions and dosimetric parameters of the target volumes and organs at risk (OARs) were recorded and compared for the three boost plans. Radiobiological metrics were calculated based on the EUD for the hybrid plans. Additionally, the relationship between tumor volume and tolerance doses for the OARs in the BT plan and CK-PTV plan was investigated. (3) Results: Target coverage was better with the CK plan than with the BT plan, as the D95%, D98%, HI and CI of the CK-CTV plan and CK-PTV plan were higher than those of the BT plan; an exception was the D50%. Similarly, the TCP of the target was also significantly in favor of the CK hybrid plans (p < 0.01). For the OARs, the CK-CTV plan was superior to the BT plan as regards the rectum D2cc, bladder D2cc and bladder Dmax. The CK-PTV plan could achieve dosimetric parameters comparable to those of the BT plan for OARs concerning the small residual tumor volume. The NTCP of the rectum for the WPI+CK-CTV plans was significantly lower than that of the WPI+BT plans (p < 0.01). (4) Conclusions: CK-based SBRT can achieve better target coverage, dose sparing for the OARs and radiobiological effects compared with the BT plan for tumors that are not excessively large. CK-based SBRT could be an alternative option to administer a radiation boost for patients with LACC.
- Open Access
- 25 January 2022
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 7 (2)
Ablation of T cell–associated PD-1H enhances functionality and promotes adoptive immunotherapy
Programmed death-1 homolog (PD-1H) is a coinhibitory molecule that negatively regulates T cell–mediated immune responses. In this study, we determined whether ablation of T cell–associated PD-1H could enhance adoptive T cell therapy in experimental tumor models. The expression of PD-1H is upregulated in activated and tumor-infiltrating CD8 + T cells. Activated CD8 + T cells from PD-1H–deficient (PD-1H–KO) mice exhibited increased cell proliferation, cytokine production, and antitumor activity in vitro. Adoptive transfer of PD-1H–KO CD8 + T cells resulted in the regression of established syngeneic mouse tumors. Similar results were obtained when PD-1H was ablated in T cells by CRISPR/Cas9-mediated gene silencing. Furthermore, ablation of PD-1H in CAR-T cells significantly improved their antitumor activity against human xenografts in vivo. Our results indicate that T cell–associated PD-1H could suppress immunity in the tumor microenvironment and that targeting PD-1H may improve T cell adoptive immunotherapy.
- 25 January 2022
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 7 (2)
Open AccessAblation of T cell–associated PD-1H enhances functionality and promotes adoptive immunotherapy
Programmed death-1 homolog (PD-1H) is a coinhibitory molecule that negatively regulates T cell–mediated immune responses. In this study, we determined whether ablation of T cell–associated PD-1H could enhance adoptive T cell therapy in experimental tumor models. The expression of PD-1H is upregulated in activated and tumor-infiltrating CD8 + T cells. Activated CD8 + T cells from PD-1H–deficient (PD-1H–KO) mice exhibited increased cell proliferation, cytokine production, and antitumor activity in vitro. Adoptive transfer of PD-1H–KO CD8 + T cells resulted in the regression of established syngeneic mouse tumors. Similar results were obtained when PD-1H was ablated in T cells by CRISPR/Cas9-mediated gene silencing. Furthermore, ablation of PD-1H in CAR-T cells significantly improved their antitumor activity against human xenografts in vivo. Our results indicate that T cell–associated PD-1H could suppress immunity in the tumor microenvironment and that targeting PD-1H may improve T cell adoptive immunotherapy.
- 1 December 2020
- Published by Institute of Electrical and Electronics Engineers (IEEE) in IEEE Transactions on Instrumentation and Measurement
- Vol. 70 (00189456) , 1-10
Feasibility Study of Permanent Magnet-Based Tumor Tracking Technique for Precise Lung Cancer Radiotherapy
During lung cancer radiotherapy, tumor motion caused by respiration and heartbeat significantly affects radiotherapy efficacy. The real-time and high-precision tracking of the lung tumor during the radiotherapy process remains a big challenge, as the traditional tracking methods have disadvantages such as slow tracking speed, radiation issue, or tracking and radiotherapy cannot be carried out at the same time. In this study, a magnetic tracking technique based on three permanent magnets was employed to localize the tumor in real-time. Thus the precise lung cancer radiotherapy is achieved by adjusting the acceleration position through the magnetic tracking results. Technical verification shows that the tracked centroid accuracies of the simulated tumor based on both 1- and 3-dipole models were 1.38 ± 0.83 mm, where the tracked tumor diameter accuracy based on the 3-dipole model was 1.51 ± 1.30 mm. The phantom experiment indicates the centroid tracking accuracies of the simulated tumor based on both 1- and 3-dipole models were 0.36 ± 0.16 mm and 2.54 ± 1.02 mm, respectively, where the tumor diameter accuracy based on the 3-dipole model was 2.15 ± 0.78 mm. Hence, this permanent magnet-based tumor tracking technique can effectively improve the performance of robotic radiotherapy. Besides, the radiotherapy object can be further expanded from lung cancer to other cancers such as prostate cancer.
- 1 December 2020
- Published by Institute of Electrical and Electronics Engineers (IEEE) in IEEE Transactions on Instrumentation and Measurement
- Vol. 70 (00189456) , 1-10
Feasibility Study of Permanent Magnet-Based Tumor Tracking Technique for Precise Lung Cancer Radiotherapy
During lung cancer radiotherapy, tumor motion caused by respiration and heartbeat significantly affects radiotherapy efficacy. The real-time and high-precision tracking of the lung tumor during the radiotherapy process remains a big challenge, as the traditional tracking methods have disadvantages such as slow tracking speed, radiation issue, or tracking and radiotherapy cannot be carried out at the same time. In this study, a magnetic tracking technique based on three permanent magnets was employed to localize the tumor in real-time. Thus the precise lung cancer radiotherapy is achieved by adjusting the acceleration position through the magnetic tracking results. Technical verification shows that the tracked centroid accuracies of the simulated tumor based on both 1- and 3-dipole models were 1.38 ± 0.83 mm, where the tracked tumor diameter accuracy based on the 3-dipole model was 1.51 ± 1.30 mm. The phantom experiment indicates the centroid tracking accuracies of the simulated tumor based on both 1- and 3-dipole models were 0.36 ± 0.16 mm and 2.54 ± 1.02 mm, respectively, where the tumor diameter accuracy based on the 3-dipole model was 2.15 ± 0.78 mm. Hence, this permanent magnet-based tumor tracking technique can effectively improve the performance of robotic radiotherapy. Besides, the radiotherapy object can be further expanded from lung cancer to other cancers such as prostate cancer.
- Open Access
- 18 December 2015
- Published by Springer Nature in Radiation Oncology
- Vol. 10 (1) , 1-8
Is the irradiated small bowel volume still a predictor for acute lower gastrointestinal toxicity during preoperative concurrent chemo-radiotherapy for rectal cancer when using intensity-modulated radiation therapy?
The small bowel (SB) represents the most important dose-limiting structure in pelvic radiotherapy (RT). However, we observed that the majority of rectal cancer patients who received preoperative pelvic intensity modulated RT (IMRT) developed acute tenesmus without watery diarrhea. The objective of this study is to determine if the RT dose to SB affects the acute lower gastrointestinal toxicity (ALGIT) in rectal cancer patients who received neoadjuvant concurrent chemotherapy-IMRT. We will also evaluate if patient and tumor factors affect the ALGIT. We retrospectively analyzed 63 rectal cancer patients that consecutively received preoperative IMRT (45 Gy for pelvis and 50 Gy for gross tumor in 25 fractions) with concurrent chemotherapy (oxaliplatin 130 mg/m2 on day 1 and capecitabine 825 mg/m2, twice per day from day 1 to day 14, week 1 and 4) between May 2012 and May 2013. The ALGIT was assessed with Common Terminology Criteria for Adverse Events version 3. The patients were stratified into two groups (with and without grade ≥2 ALGIT). The effect of SB volume receiving 5 to 40 Gy (V5 to V40) at a 5 Gy interval dose level on grade ≥2 ALGIT was evaluated. The volume of small bowel is defined as the volume of the small bowel loop. Other factors evaluated include patient’s age and gender, tumor size and location and preexisting number of daily bowel movements. Overall, grade ≥2 ALGIT occurred in 57 % (36/63) patients. There was no significant difference between the two groups of patients (with and without grade ≥2 ALGIT) in SB V5 to V40, patient’s age and gender, tumor location and preexisting number of daily bowel movements. There was a significant difference between the two groups of patients in tumor volume (with grade ≥2 ALGIT: 115.5 ± 85.5 cm3 versus without grade ≥2 ALGIT: 58.5 ± 25.2 cm3, p = 0.0001). Multivariate analysis revealed no association between the dose SB received (V5 to V40) and the grade ≥2 ALGIT after adjusting for the tumor volume. With IMRT technique used in rectal cancer patients undergoing preoperative chemo-radiotherapy, the acute lower GI toxicity is not associated with small bowel V5 to V40; instead it is associated with rectal tumor size.
- 18 December 2015
- Published by Springer Nature in Radiation Oncology
- Vol. 10 (1) , 1-8
Open AccessIs the irradiated small bowel volume still a predictor for acute lower gastrointestinal toxicity during preoperative concurrent chemo-radiotherapy for rectal cancer when using intensity-modulated radiation therapy?
The small bowel (SB) represents the most important dose-limiting structure in pelvic radiotherapy (RT). However, we observed that the majority of rectal cancer patients who received preoperative pelvic intensity modulated RT (IMRT) developed acute tenesmus without watery diarrhea. The objective of this study is to determine if the RT dose to SB affects the acute lower gastrointestinal toxicity (ALGIT) in rectal cancer patients who received neoadjuvant concurrent chemotherapy-IMRT. We will also evaluate if patient and tumor factors affect the ALGIT. We retrospectively analyzed 63 rectal cancer patients that consecutively received preoperative IMRT (45 Gy for pelvis and 50 Gy for gross tumor in 25 fractions) with concurrent chemotherapy (oxaliplatin 130 mg/m2 on day 1 and capecitabine 825 mg/m2, twice per day from day 1 to day 14, week 1 and 4) between May 2012 and May 2013. The ALGIT was assessed with Common Terminology Criteria for Adverse Events version 3. The patients were stratified into two groups (with and without grade ≥2 ALGIT). The effect of SB volume receiving 5 to 40 Gy (V5 to V40) at a 5 Gy interval dose level on grade ≥2 ALGIT was evaluated. The volume of small bowel is defined as the volume of the small bowel loop. Other factors evaluated include patient’s age and gender, tumor size and location and preexisting number of daily bowel movements. Overall, grade ≥2 ALGIT occurred in 57 % (36/63) patients. There was no significant difference between the two groups of patients (with and without grade ≥2 ALGIT) in SB V5 to V40, patient’s age and gender, tumor location and preexisting number of daily bowel movements. There was a significant difference between the two groups of patients in tumor volume (with grade ≥2 ALGIT: 115.5 ± 85.5 cm3 versus without grade ≥2 ALGIT: 58.5 ± 25.2 cm3, p = 0.0001). Multivariate analysis revealed no association between the dose SB received (V5 to V40) and the grade ≥2 ALGIT after adjusting for the tumor volume. With IMRT technique used in rectal cancer patients undergoing preoperative chemo-radiotherapy, the acute lower GI toxicity is not associated with small bowel V5 to V40; instead it is associated with rectal tumor size.